Emerging innovations in theranostics for pancreatic neuroendocrine tumors
Authors:
Open Access
- 19 May 2025
- journal article
- review article
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-12
Abstract
Pancreatic neuroendocrine tumors (pNETs) often overexpress somatostatin receptor type 2 (SSTR2), making them ideal targets for theranostics, which integrates molecular imaging with targeted radionuclide therapy. 177Lu-DOTATATE significantly extends progression-free survival (22.8 vs. 8.5 months) compared to octreotide LAR. Despite these advances, challenges remain, including treatment resistance and long-term toxicities. In this review, we explore advancements in specialized imaging techniques, rationale combination strategies, and exploring next-generation radiopharmaceuticals.Keywords
Funding Information
- Cancer Research and Treatment Fund
- U.S. Department of War
- National Institutes of Health
This publication has 126 references indexed in Scilit:
- Survival impact of [225Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATEEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETestEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Pancreatic neuroendocrine tumorsCancer, 2009
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008